UnitedHealth Group (UNH) is the largest health insurer in the United States and, by revenue, one of the largest companies on earth. Based in Eden Prairie, Minnesota, it reported $447.6 billion in revenue for fiscal 2025 (UnitedHealth Group 2026), insures roughly 50 million Americans through its UnitedHealthcare subsidiary, and runs Optum, a health services conglomerate that processes claims, manages pharmacy benefits, and employs or affiliates with physicians serving hundreds of millions more. What makes UNH interesting right now is not its scale but its condition: operating income fell from $32.3 billion in 2024 to $19.0 billion in 2025, diluted EPS dropped to $13.23 from $23.86 in 2023, and all three major credit agencies put the company on negative outlook. Behind those numbers sits a convergence of four simultaneous crises: a ransomware attack that disrupted the entire U.S. healthcare claims system and will cost the company north of $3 billion in total; the murder of UnitedHealthcare’s CEO outside a Manhattan hotel in December 2024; a Medicare Advantage cost spiral that destroyed $20 billion in annualized earnings power; and a Department of Justice investigation with both criminal and civil dimensions. Whether this is a permanently impaired business or a temporarily broken situation inside a structurally durable one is the central question this post tries to answer.
A Company Built by Acquisition
UnitedHealth Group traces its roots to 1977, when Richard T. Burke founded United HealthCare Corporation in Minnetonka, Minnesota. The original business was modest: a management company overseeing a physicians’ HMO program in the state. The timing was deliberate. Four years earlier, Congress had passed the HMO Act of 1973, which required employers with 25 or more employees to offer an HMO option alongside traditional insurance. The legislation was heavily influenced by Dr. Paul Ellwood Jr., a Minneapolis physician who coined the term “Health Maintenance Organization” and argued that prepaid group health plans could simultaneously reduce costs and improve outcomes. Burke saw the opportunity to build a management layer on top of this new model.
The company went public in 1984. Through the late 1980s and early 1990s, United HealthCare grew by acquiring regional HMOs across the country, rolling up fragmented local plans into a national footprint. The transformational deal came in 1995: the acquisition of Metrahealth, the combined health benefits business of Metropolitan Life and Travelers, for $1.65 billion. Metrahealth brought millions of members and a national employer network. The deal vaulted United HealthCare from a regional managed care company into one of the largest health insurers in the country virtually overnight.
In 1998, the company renamed itself UnitedHealth Group to reflect what it had become: not a single HMO, but a diversified health services holding company. The name change also signaled ambition. Management wanted the market to understand this was a platform, not just an insurance carrier.
How Hemsley Built Optum
Stephen Hemsley joined UnitedHealth Group as CFO in 1997 and rose quickly through the ranks: COO, then President, then CEO in 2006. His tenure would fundamentally reshape the company.
Hemsley’s central insight was that the data, technology, and care delivery capabilities embedded inside a health insurer had value far beyond the insurance operation itself. Hospitals needed analytics to manage their revenue cycles. Employers needed tools to understand healthcare spending. Competing health insurers needed claims processing infrastructure. Physicians needed practice management support. All of these buyers would pay for services that UNH had already built for its own internal use.
Rather than keeping these capabilities as internal support functions, Hemsley spun them into a standalone business unit: Optum. The name first appeared in 2011, when UNH rebranded its health data subsidiary Ingenix as OptumInsight. The pharmacy benefits management operation became OptumRx. The growing network of physician practices, surgical centers, and home health providers became Optum Health.
This created inherent tension. Optum’s clients included UNH’s own insurance competitors. Aetna, Cigna, and Humana were simultaneously competing with UnitedHealthcare for members while buying analytics, claims processing, and pharmacy management services from Optum. This made competitors uncomfortable, but Optum’s scale and capabilities were difficult to replicate. The switching costs were high, the data advantages were real, and building an alternative from scratch would take years and billions of dollars.
By the time Hemsley transitioned to Executive Chairman in 2017, Optum had grown from an internal cost center into a business generating over $90 billion in annual revenue. It was already more profitable than many standalone Fortune 100 companies.
Change Healthcare: A $13 Billion Bet on Data
Andrew Witty took over as CEO in 2021 after spending his career at GlaxoSmithKline, where he eventually ran the pharmaceutical giant. His appointment reflected UNH’s self-image as a healthcare company that happened to have an insurance arm.
Witty doubled down on two bets Hemsley had planted. The first was value-based care, where Optum Health’s physicians accept a fixed monthly payment per patient and take on financial responsibility for that patient’s total healthcare costs. If costs come in below the fixed payment, Optum keeps the difference. If costs run over, Optum absorbs the loss.
The second bet was the $13 billion acquisition of Change Healthcare, completed in October 2022 after a protracted antitrust fight with the DOJ. Change Healthcare processed roughly 15 billion healthcare transactions per year. Its clearinghouse systems sat between providers and payers, routing insurance claims, verifying eligibility, and facilitating payments.
The strategic logic was straightforward: combining Change Healthcare’s transaction data with Optum Insight’s analytics would give UNH unparalleled visibility into healthcare spending patterns across the entire industry. The DOJ tried to block the deal on antitrust grounds, arguing that UNH would gain access to competitors’ proprietary claims data. A federal judge disagreed and allowed the merger to proceed.
Two Businesses Under One Roof
UnitedHealth Group operates two distinct businesses that share a name, a balance sheet, and $168 billion in annual intercompany transactions. Understanding the company requires understanding each one separately.
UnitedHealthcare: The Insurance Side
UnitedHealthcare is the largest health insurance company in the United States, serving 49.76 million people domestically as of December 31, 2025 (UnitedHealth Group 2026). It operates across three lines of business.
Employer & Individual is the traditional commercial insurance operation. It covers 29.7 million members and generated $79.2 billion in revenue in 2025. This is the business most people picture when they think of health insurance: the plan your employer offers, the network of doctors you can see, the card you hand to the receptionist. About two-thirds of these members are in self-insured arrangements where the employer takes the financial risk and UNH administers the plan for a fee. The remaining third are fully insured, meaning UNH collects the premium and bears the risk that medical costs exceed what it collected.
Medicare & Retirement is the largest segment by revenue at $171.3 billion and the most consequential for UNH’s financial trajectory. UNH is the largest Medicare Advantage plan in the country with 8.4 million members. It also covers 10.4 million Medicare Part D prescription drug enrollees and 4.3 million Medicare Supplement members. Under Medicare Advantage, CMS pays UNH a fixed monthly amount per enrollee, adjusted for the enrollee’s health status through a process called risk adjustment. Sicker patients generate higher payments. This risk-adjustment mechanism is at the center of the DOJ investigation.
A single number captures how important this relationship is: premium revenues from CMS represent 44% of UNH’s total consolidated revenues. The federal government is UNH’s largest customer by a wide margin.
Community & State manages Medicaid programs in 32 states and the District of Columbia, covering 7.4 million members and generating $94.4 billion in revenue. These are contracts with state governments to manage healthcare for low-income and medically complex populations. The economics depend heavily on how accurately state-set reimbursement rates reflect the actual health needs of the enrolled population.
Optum: The Services Empire
Optum is the part of UNH that makes the company unique among health insurers. No competitor has anything comparable in scale or scope. It operates three divisions.
Optum Health is the care delivery arm. It generated $102 billion in revenue in 2025 and serves 95 million people through a network of owned and affiliated physician practices, surgical centers, home health providers, urgent care clinics, and virtual care platforms. The business model is increasingly built around value-based care: Optum’s physicians accept financial responsibility for a patient population’s total healthcare costs in exchange for a fixed monthly payment. When medical costs come in below that fixed payment, the margin is attractive. When costs run above it, the losses flow directly to the income statement. In 2024, Optum Health generated $7.8 billion in operating income. In 2025, it posted a $278 million operating loss. That $8 billion swing in a single year is the clearest illustration of the risk embedded in this model.
Optum Insight is the technology and data analytics business. It reported $19.4 billion in revenue and $2.6 billion in operating income in 2025. This is where Change Healthcare now lives, running the claims clearinghouse infrastructure that routes transactions between providers and payers across the country. Optum Insight also provides revenue cycle management software to hospitals, analytics platforms for health plans, and managed services for government agencies. The segment carries a $31 billion backlog of contracted future revenues, providing meaningful visibility into future earnings.
Optum Rx is the pharmacy benefits manager. It is the most reliably profitable piece of UNH, generating $154.7 billion in revenue and $7.2 billion in operating income in 2025. Optum Rx managed $188 billion in pharmaceutical spending and fulfilled 1.659 billion adjusted prescription scripts during the year, up from 1.623 billion in 2024. The PBM business benefits from enormous scale advantages: the more prescriptions it manages, the more negotiating leverage it has with drug manufacturers and pharmacies, and the harder it becomes for clients to leave.
What makes UNH both powerful and controversial is the interplay between these businesses. UnitedHealthcare pays Optum Rx to manage its members’ prescriptions. It pays Optum Health to provide care to its members. It pays Optum Insight to process its claims. Those intercompany transactions totaled $168 billion in 2025. Critics argue this creates conflicts of interest and an unfair competitive advantage. UNH argues it creates efficiencies that lower costs for consumers. Both are probably right.
What Went Wrong
A Ransomware Attack on National Healthcare Infrastructure
On February 21, 2024, the Change Healthcare platform was hit by a ransomware attack attributed to the BlackCat/ALPHV criminal group. The attackers compromised the network, encrypted critical systems, and effectively shut down the infrastructure that processed tens of billions of dollars in healthcare claims annually.
Hospitals, physician practices, and pharmacies across the country lost the ability to process insurance claims. Small independent practices, which often operate on thin cash reserves, faced genuine solvency crises within days. Pharmacies struggled to verify insurance coverage for prescriptions. The attack did not just disrupt UNH’s operations; it disrupted the American healthcare payment system.
UNH’s response included standing up an interest-free loan program for affected healthcare providers to keep them solvent while claims were stuck in the system. By the end of 2024, the company had advanced $9 billion to care providers through this program. By the end of 2025, only $1.68 billion had been repaid. In Q4 2025, UNH took an additional $799 million reserve for expected losses on those loans, an acknowledgment that a meaningful portion of the $9 billion may not come back.
Beyond the operational disruption, the attackers exfiltrated protected health information belonging to an estimated 100 million Americans, making it the largest healthcare data breach in U.S. history. Class action lawsuits, state attorney general investigations, congressional hearings, and regulatory inquiries followed. Total direct costs related to the cyberattack through the end of 2025 are roughly $3.3 billion, spanning response costs, provider loan losses, legal expenses, and system remediation.
The breach also exposed a structural vulnerability: the entire U.S. healthcare claims system had become dependent on infrastructure owned by a single company. When Change Healthcare went down, there was no backup.
CEO Assassination and Its Regulatory Fallout
On December 4, 2024, Brian Thompson, CEO of the UnitedHealthcare subsidiary, was shot and killed outside a Manhattan hotel as he walked to an investor conference. Thompson was 50 and had led UnitedHealthcare since 2021.
The killing’s business impact was twofold. First, UNH lost the head of its largest subsidiary during the most operationally challenging period in the company’s history. Tim Noel, who had led UnitedHealthcare’s Medicare & Retirement business, was named replacement CEO effective January 2025. Second, the event intensified political scrutiny of health insurance practices in ways that will affect UNH’s operating environment for years. Congressional attention to claim denial rates and prior authorization practices accelerated. Multiple state legislatures introduced bills targeting insurer practices. The reputational damage compounded the regulatory pressure UNH was already facing from the Change Healthcare breach and the DOJ investigation.
Six Points of MCR Deterioration
The crisis with the largest financial impact received the least public attention: medical costs were running far above the levels assumed when premiums were set.
The core metric in health insurance is the MCR, the percentage of premium revenue paid out in medical claims. In 2023, UNH’s MCR was 83.2%. In 2024, it rose to 85.5%. In 2025, it reached 89.1%. On a base of $352 billion in premium revenue, each percentage point of MCR represents roughly $3.5 billion in additional medical costs. The six-point deterioration from 2023 to 2025 translates to roughly $21 billion in annualized profit destruction relative to where the company was two years ago.
Several forces converged to drive this.
Medicare Advantage rate suppression. For several consecutive years, CMS set payment rates for Medicare Advantage plans below the actual trend in medical costs. CMS was attempting to correct what it viewed as overpayments driven by risk-adjustment coding practices, where plans submit diagnosis codes that generate higher per-member payments. The result was a multi-year squeeze: UNH was locked into premium rates that proved inadequate for the actual medical costs its members incurred.
Post-pandemic care catch-up. Patients who deferred care during COVID-19 returned to healthcare settings with more complex, higher-acuity conditions. The sickest patients, particularly in Medicare Advantage, turned out to be considerably sicker than actuarial models had predicted.
Inflation Reduction Act changes to Medicare Part D. The 2022 legislation overhauled Medicare prescription drug coverage, shifting more financial risk to health plans and altering both the cost profile and seasonal pattern of drug spending. UNH’s Part D membership grew to 10.4 million enrollees, but the economics of serving those enrollees changed meaningfully under the new structure.
Value-based care overruns at Optum Health. UNH had been aggressively expanding its fully accountable value-based care model, where Optum takes on financial responsibility for a patient population’s total healthcare costs. When actual costs exceed the fixed payment, the losses flow directly to the income statement. Optum Health swung from $7.8 billion in operating income in 2024 to a $278 million operating loss in 2025. An $8 billion deterioration in a single segment in a single year.
Medicaid acuity mismatch. As states resumed Medicaid eligibility redeterminations after the COVID-era pause, the members who retained coverage tended to be disproportionately sick. State reimbursement rates did not adequately reflect this shift in the population’s health status, turning UNH’s Medicaid business into a money-loser in several markets.
None of these factors appeared overnight, but they compounded simultaneously. The result was a company earning less than half its 2023 operating margin on 20% more revenue.
DOJ Criminal and Civil Investigation
In July 2025, UNH disclosed that it had “proactively reached out to the Department of Justice” after reviewing media reports about investigations into certain aspects of the company’s participation in the Medicare program. The company confirmed it had begun complying with “formal criminal and civil requests” from the Department (UnitedHealth Group 2025c).
That word “criminal” matters. Civil investigations can result in monetary penalties. Criminal investigations can result in indictments, guilty pleas, and structural remedies that fundamentally alter how a company operates.
A whistleblower lawsuit was originally filed under seal in 2011, alleging that UNH made improper risk-adjustment submissions to CMS and violated the False Claims Act. The DOJ joined the case in February 2017, giving it the full weight of federal prosecution resources.
At issue is how Medicare Advantage risk adjustment works. CMS pays Medicare Advantage plans a monthly amount per enrollee, adjusted upward for sicker patients based on diagnosis codes submitted by the plan. The government’s theory is that UNH systematically submitted diagnosis codes that inflated the health risk of its members, causing CMS to overpay. UNH’s position is that its coding practices are accurate and that independent CMS audits confirm its practices are “among the most accurate in the industry.”
After nearly a decade of litigation, a court-appointed Special Master issued a report in March 2025 recommending summary judgment in UNH’s favor on all remaining claims. That should have been welcome news, but a month later the DOJ filed a motion asking the court to reject the Special Master’s findings. The case remains unresolved.
UNH’s disclosure language around potential liability is carefully vague: it “cannot reasonably estimate the outcome” of the investigations (UnitedHealth Group 2026). Under False Claims Act provisions, liability can include treble damages (three times actual damages) plus per-claim penalties. If the government establishes that improper coding occurred across millions of enrollees over many years, theoretical liability runs into the tens of billions. In practice, a company of UNH’s systemic importance would almost certainly negotiate a settlement rather than face a judgment of that magnitude. But the range of possible outcomes is wide, and the criminal dimension adds a layer of uncertainty that civil proceedings alone would not.
CMS also conducts RADV audits of Medicare Advantage plans, examining whether submitted diagnosis codes are supported by medical records. These audits have been ongoing and could result in additional retrospective payment reductions independent of the False Claims Act case.
UNH struck a confident tone in the 8-K: it has “full confidence in its practices” and pointed to the Special Master’s findings as evidence (UnitedHealth Group 2025c). But confidence and resolution are different things, and this investigation will hang over the company until it concludes.
Hemsley Returns at 73
On May 12, 2025, Andrew Witty stepped down as CEO, effective immediately. The 8-K disclosure was terse: Witty “notified the Company of his decision to step down” and would continue as a “senior advisor to the new Chief Executive Officer” (UnitedHealth Group 2025b).
The board replaced him with Stephen Hemsley, then 73 years old and serving as Non-Executive Chairman. Hemsley had built Optum during his original tenure as CEO from 2006 to 2017. He understood the architecture of every business inside the company because he had designed most of it. Bringing back a former CEO in his seventies is a stabilization move, not a growth signal.
Hemsley’s compensation package reinforced this interpretation (UnitedHealth Group 2025b). He accepted a $1 million annual base salary with no annual cash incentive. In lieu of recurring equity grants, he received a one-time $60 million stock option grant with cliff vesting after three years and no additional annual equity awards during that period. The structure aligns Hemsley entirely with long-term stock price recovery. If the stock does not recover, the options are worthless. If it does, $60 million in options could be worth multiples of that.
UNH also brought in Wayne DeVeydt as CFO in September 2025. DeVeydt had previously served as CFO of Anthem (now Elevance Health), giving him deep familiarity with the managed care business and the specific Medicare Advantage dynamics pressuring UNH’s results. The combination of Hemsley and DeVeydt represents a team specifically assembled to manage crisis and restructuring, not to sell a growth narrative.
Additional officer changes appeared in quick succession in early 2026, suggesting the leadership reshuffling extended well beyond the C-suite. The full extent of management turnover beneath the CEO and CFO level is not yet fully visible.
Financial Profile
Revenue Growth Masking Margin Collapse
| Year | Total Revenue | Growth | UnitedHealthcare | Optum |
|---|---|---|---|---|
| 2023 | $371.6B | $281.4B | $226.6B | |
| 2024 | $400.3B | 7.7% | $298.2B | $253.0B |
| 2025 | $447.6B | 11.8% | $344.9B | $270.6B |
Revenue growth has been consistent and, in isolation, impressive. The 2025 increase was driven primarily by Medicare Advantage membership growth, the expansion of Medicare Part D premiums under the Inflation Reduction Act’s restructured benefit design, and continued organic growth at Optum Rx. But revenue growth at a health insurer can be a warning sign rather than a positive one. When medical costs are rising faster than premiums, adding members at inadequate rates accelerates losses rather than generating profit. That is exactly what happened in 2025.
Profitability Collapse by Segment
| Year | Operating Income | Operating Margin | MCR | Diluted EPS |
|---|---|---|---|---|
| 2023 | $32.4B | 8.7% | 83.2% | $23.86 |
| 2024 | $32.3B | 8.1% | 85.5% | $15.51 |
| 2025 | $19.0B | 4.2% | 89.1% | $13.23 |
The 2024 EPS figure of $15.51 is distorted by an $8.3 billion loss on the divestiture of UNH’s Brazil operations, which depresses per-share earnings but is not recurring. Operating income in 2024 was essentially flat with 2023. The real deterioration hit in 2025.
Operating margin fell from 8.7% to 4.2% in two years. On a revenue base of $447.6 billion, that margin compression represents roughly $20 billion in annualized earnings destruction. The segment-level detail reveals where the damage is concentrated:
| Segment | 2024 Op Income | 2025 Op Income | Change |
|---|---|---|---|
| UnitedHealthcare | $12.3B | $9.4B | -$2.9B |
| Optum Health | $7.8B | ($0.3B) | -$8.1B |
| Optum Insight | $2.5B | $2.6B | +$0.1B |
| Optum Rx | $6.9B | $7.2B | +$0.3B |
| Corporate | ($2.7B) | ($4.5B) | -$1.8B |
Two segments account for nearly all the damage. UnitedHealthcare’s $2.9 billion decline reflects the MCR spike across all lines of business. Optum Health’s $8.1 billion swing from profit to loss is the value-based care model absorbing medical costs it was not built to handle at current reimbursement levels. Optum Insight and Optum Rx, by contrast, were stable to slightly growing. Corporate overhead increased by $1.8 billion, driven largely by the $2.5 billion Q4 restructuring charge.
Balance Sheet: Scale and Leverage
| Item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash & Equivalents | $24.4B | $25.3B |
| Short-term Investments | $3.8B | similar |
| Long-term Investments | $54.3B | similar |
| Total Assets | $309.6B | $298.3B |
| Goodwill | $110.5B | $106.7B |
| Other Intangibles | $20.5B | $23.3B |
| Total Debt | $77.7B | $76.2B |
| Medical Costs Payable | $39.3B | $34.2B |
| Total Equity | $100.1B | $98.3B |
Debt. $77.7 billion in total borrowings, with $6.1 billion maturing in 2026, $3.5 billion in 2027, and $3.6 billion in 2028. Annual interest expense runs at $4 billion. Net debt (total debt minus cash) is roughly $53 billion. In June 2025, the company issued $3 billion in new notes across four tranches, with maturities ranging from 2028 to 2055 and coupon rates from 4.40% to 5.95% (UnitedHealth Group 2025a). The company has no trouble accessing debt markets, but it is paying up for the privilege. All three major credit rating agencies, Moody’s (A2), S&P (A+), and Fitch (A), maintain investment grade ratings but all three carry negative outlooks. A downgrade would raise borrowing costs on the entire $78 billion stack and could trigger complications in the commercial paper market UNH relies on for short-term funding.
Goodwill. At $110.5 billion, goodwill represents 36% of total assets. This is the accumulated premium paid over book value across decades of acquisitions, including the $13 billion Change Healthcare deal. The company stress-tested goodwill for impairment as of October 2025 and found none, but a sustained decline in earnings power or a change in discount rate assumptions could trigger a write-down. A goodwill impairment would not affect cash flow, but it would reduce reported equity and increase leverage ratios.
Medical costs payable. This reserve grew from $34.2 billion to $39.3 billion, a $5.1 billion increase that reflects the higher MCR environment. The company recorded only $140 million in favorable prior-year reserve development in 2025, down from $700 million in 2024. Shrinking favorable development means reserves are being set with less margin for error, or that prior reserves are proving less conservative than they once were.
Regulated subsidiary capital. UNH’s insurance and HMO subsidiaries held $43.1 billion in statutory capital against a regulatory requirement of $23.2 billion. The $19.9 billion excess provides substantial cushion. But the direction of capital flows tells an important story. In 2024, UNH extracted $9.2 billion net from its regulated subsidiaries (dividends from subsidiaries to the parent, minus capital contributions). In 2025, it was a net contributor of $535 million. That is a $9.7 billion swing in one year and a sign of just how much financial pressure the insurance subsidiaries are under.
Cash Flow and Capital Returns
| Item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating Cash Flow | $19.7B | $24.2B | $29.0B |
| Capital Expenditures | $3.6B | $3.9B | $3.6B |
| Free Cash Flow | $16.1B | $20.3B | $25.4B |
| Dividends Paid | $7.9B | $7.4B | $6.7B |
| Share Repurchases | $5.5B | $10.2B | $11.2B |
| Total Capital Returns | $13.4B | $17.6B | $17.9B |
Operating cash flow has fallen 32% over two years, from $29.0 billion to $19.7 billion. Free cash flow dropped from $25.4 billion to $16.1 billion over the same period. The company has partially adjusted by cutting share repurchases nearly in half, from $11.2 billion in 2023 to $5.5 billion in 2025. The buybacks executed in 2025 were done at an average price of $454.82 per share, which may or may not look wise depending on where the stock lands in two years.
Dividends, on the other hand, have continued to grow. The annual dividend reached $8.84 per share in 2025, up from $7.52 in 2024. On 906 million shares, that represents $7.9 billion in annual cash outflow. Combined with the reduced but still substantial buyback program, total capital returns of $13.4 billion consume 83% of free cash flow. That leaves limited room for error. If the MCR stays elevated through 2026 and operating cash flow deteriorates further, UNH will face a choice between cutting the buyback program to zero, slowing dividend growth, or increasing leverage.
The company also spent $4.5 billion on acquisitions in 2025, though this was partially offset by $3.4 billion in divestiture proceeds as UNH exited underperforming businesses. The acquisition activity is notably lower than prior years, suggesting management is conserving capital rather than pursuing growth deals during the crisis period.
Days in claims payable increased to 48.9 from 47.7 in 2024 and 46.0 in 2023. Stretching payment timelines preserves cash in a deteriorating MCR environment, but it strains provider relationships and invites regulatory scrutiny.
Q4 2025: Clearing the Decks
Q4 2025 was the quarter where management decided to stop defending the trajectory and start resetting expectations. The company recorded $2.5 billion in restructuring and related charges, concentrated in several categories:
| Item | Amount |
|---|---|
| Real estate rationalization & workforce reductions | $746M |
| Contractual reassessments | $573M |
| Loss contract reserves (value-based care) | $623M |
| United Health Foundation advance funding | $250M |
| Equity security write-downs | $329M |
Loss contract reserves are the most telling line item. When a company establishes a loss contract reserve, it is acknowledging that specific contracts currently on the books are expected to lose money over their remaining term. The $623 million reserve covers value-based care arrangements where Optum Health has committed to provide care at a fixed price that is now expected to fall below the actual cost of delivering that care. These contracts cannot simply be exited overnight. They must be managed through to expiration or renegotiated.
An additional $799 million in cyberattack-related reserves, booked separately from the restructuring charges, covers expected losses on the provider loan program that originated during the Change Healthcare outage. Combined with the restructuring charges, Q4 2025 carried roughly $3.3 billion in items that management is framing as non-recurring.
Management may be clearing the decks: acknowledging every known problem in a single quarter, taking the accounting pain upfront, and creating a clean baseline from which to measure recovery. Under this reading, Q4 2025 is the trough, and the comparison period for 2026 will look favorable by contrast.
Or: items labeled “non-recurring” have a way of recurring. The MCR is still elevated. The value-based care model has structural issues that a one-time reserve does not solve. The DOJ investigation is unresolved. And UNH entered 2026 without providing full-year earnings guidance, a break from years of consistent and reliable guidance. A company that is confident in its trajectory provides guidance. A company taking a kitchen-sink quarter and simultaneously withdrawing guidance is telling you that visibility is genuinely poor.
UNH also sold several underperforming businesses during Q4, booking a $568 million net gain from divestitures that partially offset the restructuring charges in reported earnings. Asset sales during reset quarters are a common pattern: soften the headline number while clearing out businesses that no longer fit.
Valuation
The goal here is to estimate what UNH should be worth based on fundamentals, without reference to the current stock price or analyst opinions. 2025 earnings are clearly not representative of the company’s normalized earning power. The harder question is what “normalized” actually means for a company facing this many simultaneous pressures.
Establishing Normalized Earnings
Reported 2025 operating income was $19.0 billion. Several items distort that number in both directions.
| Adjustment | Amount |
|---|---|
| Reported operating income | $19.0B |
| Add back: restructuring charges | +$2.5B |
| Add back: cyberattack reserves | +$0.8B |
| Subtract: divestiture gains | -$0.6B |
| Adjusted 2025 operating income | $21.7B |
That $21.7 billion still reflects an MCR of 89.1% and an Optum Health segment posting an operating loss. Neither of those conditions is sustainable, but neither will correct overnight. The relevant question is where each segment settles over the next two to three years.
UnitedHealthcare earned $9.4 billion in operating income in 2025, down from $12.3 billion in 2024. MCR recovery depends on CMS Medicare Advantage rate actions, the company’s ability to reprice commercial and Medicaid books, and the exit from unprofitable markets. A realistic normalized range is $12 to $14 billion, reflecting partial MCR recovery to the 86 to 87% range rather than a full return to 2023’s 83.2%.
Optum Health posted a $278 million operating loss in 2025 after earning $7.8 billion in 2024. The loss contract reserves suggest management knows which contracts are underwater, and the restructuring signals an intent to exit or renegotiate them. A normalized range of $5 to $7 billion in operating income assumes the business recovers but does not return to peak margins, because some of the aggressive value-based care expansion was genuinely mispriced.
Optum Insight and Optum Rx were stable at $2.6 billion and $7.2 billion respectively. Both should grow modestly. A combined normalized range of $10 to $12 billion is reasonable.
Corporate overhead ran at $4.5 billion in 2025 due to restructuring. A normalized level is closer to $2.7 to $3.0 billion.
| Segment | 2025 Actual | Normalized Range |
|---|---|---|
| UnitedHealthcare | $9.4B | $12-14B |
| Optum Health | ($0.3B) | $5-7B |
| Optum Insight | $2.6B | $2.8-3.2B |
| Optum Rx | $7.2B | $7.5-8.5B |
| Corporate | ($4.5B) | ($2.7-3.0B) |
| Total | $14.5B | $24.6-29.7B |
After interest expense of $4 billion and taxes at a 21% effective rate, normalized net income falls in a range of $16.3 to $20.3 billion, or roughly $18 to $22.40 per share on 906 million diluted shares.
Scenario-Based Valuation
Method 1: P/E on Normalized Earnings
What multiple UNH deserves depends on two factors: the quality and growth trajectory of the underlying businesses, and the discount required for the legal and regulatory uncertainty currently hanging over the company.
At its peak, UNH traded at 20 to 25 times earnings, reflecting consistent double-digit earnings growth, a dominant market position, and the Optum growth engine. That multiple is not available today. The company has broken its earnings trajectory, suspended guidance, and faces an open criminal investigation. A recovery multiple in the 14 to 18 times range is more appropriate, reflecting an assumption that UNH is still a structurally sound business that will recover, but that the path to recovery is uncertain and the regulatory environment has become more hostile.
| Scenario | Normalized EPS | Multiple | Value Per Share |
|---|---|---|---|
| Bear | $14-16 | 12x | $168-192 |
| Base | $18-20 | 15x | $270-300 |
| Bull | $22-25 | 18x | $396-450 |
The bear case assumes MCR remains elevated above 87%, Optum Health recovers only partially, and the DOJ investigation results in a material settlement. The base case assumes MCR normalizes to 86 to 87% over two to three years, Optum Health returns to $5 to $6 billion in operating income, and the DOJ resolves through a civil settlement in the single-digit billions. The bull case assumes full MCR normalization, Optum Health returns to near-peak profitability, and the DOJ case is resolved favorably.
Method 2: Sum of Parts
UNH’s businesses have fundamentally different risk profiles and growth characteristics, making a sum-of-parts approach useful as a cross-check.
| Segment | Normalized Op Income | EV Multiple | Enterprise Value |
|---|---|---|---|
| UnitedHealthcare | $13B | 10-11x | $130-143B |
| Optum Health | $6B | 12-14x | $72-84B |
| Optum Insight | $3B | 15-17x | $45-51B |
| Optum Rx | $8B | 8-9x | $64-72B |
| Corporate | ($3B) | 10x | ($30B) |
| Total Enterprise Value | $281-320B | ||
| Less: Net Debt | ($53B) | ||
| Equity Value | $228-267B | ||
| Per Share (906M) | $252-295 |
Optum Rx gets the lowest multiple despite being the most profitable segment because PBMs face rising regulatory scrutiny and potential legislative action targeting the spread-pricing model. Optum Insight gets the highest multiple because recurring technology revenue with a $31 billion backlog commands a premium. UnitedHealthcare is valued as a regulated insurance business with limited upside to margins.
Method 3: Free Cash Flow Yield
Even in a depressed year, UNH generated $16.1 billion in free cash flow. In a normalized environment, free cash flow should track closer to $18 to $22 billion. The appropriate yield depends on how much uncertainty the investor demands compensation for.
| Yield Assumption | Normalized FCF | Implied Equity Value | Per Share |
|---|---|---|---|
| 8% (high uncertainty) | $18B | $225B | $248 |
| 6.5% (moderate uncertainty) | $20B | $308B | $340 |
| 5.5% (lower uncertainty) | $22B | $400B | $441 |
Pricing the DOJ Investigation
The DOJ investigation is the widest variable in the valuation. The range of outcomes spans from dismissal to a multi-billion dollar settlement with structural remedies. Because this is a binary risk that cannot be modeled with precision, a probability-weighted approach is the most honest way to handle it.
| Scenario | Probability | Settlement/Penalty | Per Share Impact |
|---|---|---|---|
| Favorable resolution (dismissed or minimal penalty) | 15% | $0-2B | $0-2 |
| Moderate civil settlement | 45% | $5-10B | $6-11 |
| Large civil settlement with operational constraints | 25% | $15-25B | $17-28 |
| Criminal charges against individuals, large civil resolution | 10% | $10-20B (plus reputational damage) | $15-25 |
| Catastrophic outcome (treble damages, structural remedies) | 5% | $40-80B | $44-88 |
Probability-weighted expected cost: $10 to $16 billion, or roughly $11 to $18 per share.
A few notes on the reasoning behind these probabilities.
A 15% chance of favorable resolution reflects the Special Master’s recommendation in UNH’s favor, which is a meaningful data point. Courts do not always follow Special Master recommendations, but they rarely disregard them entirely. The DOJ’s decision to reject the recommendation and press forward suggests confidence in the government’s case, or at least institutional commitment to pursuing it.
Moderate civil settlement gets the highest probability because this is how most False Claims Act cases involving large healthcare companies resolve. The government and the company negotiate a dollar figure, the company neither admits nor denies wrongdoing, and both sides issue press releases declaring victory. For UNH, a $5 to $10 billion settlement would be painful but manageable given the company’s cash generation. It would represent roughly one to two years of reduced capital returns.
A 5% probability for the catastrophic outcome deserves explanation. Under the False Claims Act, liability can include treble damages plus per-claim penalties. If the government could establish that UNH systematically inflated risk-adjustment scores across millions of Medicare Advantage enrollees over a decade or more, the theoretical liability could exceed $100 billion. In practice, no court would enter a judgment that bankrupts the largest health insurer in the country and disrupts coverage for 50 million Americans. But the theoretical exposure creates negotiating leverage for the DOJ, and the criminal dimension introduces risks that civil proceedings alone would not.
Per-share impact is calculated after-tax, assuming settlements are partially deductible as business expenses. This is a simplification; the tax treatment depends on the specific terms of any resolution.
Putting It Together
| Method | Bear | Base | Bull |
|---|---|---|---|
| P/E on Normalized Earnings | $168-192 | $270-300 | $396-450 |
| Sum of Parts | $252-295 | ||
| FCF Yield | $248 | $340 | $441 |
| Average (pre-DOJ) | $200 | $305 | $430 |
| DOJ Discount | ($30) | ($15) | ($5) |
| Final Range | $170 | $290 | $425 |
Base case lands at roughly $290 per share. The sum-of-parts methodology pulls this a bit lower, the FCF yield pushes it a bit higher, and the P/E approach sits in the middle. The DOJ discount in the base case is modest because the most likely outcome is a negotiated settlement that is painful but not existential.
That range is wide on purpose. A company facing an open criminal investigation, an MCR that has not yet stabilized, suspended earnings guidance, and a new-old CEO executing a turnaround does not lend itself to precision. Anyone who gives you a single number for what UNH is worth right now is more confident than the facts warrant.
If you found this helpful, consider supporting my work. This blog has no ads and no paywalled content, and reader support is how it stays that way. You can also subscribe to my mailing list to get new deep dives in your inbox.
What to Watch
| Catalyst | Why It Matters | Timeline |
|---|---|---|
| Q1 2026 earnings | First data point on whether the MCR is stabilizing in 2026; sets the tone for whether guidance will be reinstated | Late April 2026 |
| CMS Medicare Advantage Final Notice | Annual rate-setting that determines 2027 Medicare Advantage economics; the Advance Notice was described as “far below” expected medical cost trend | April 2026 |
| DOJ investigation developments | Court ruling on the Special Master’s recommendation; any criminal charging decisions; settlement discussions | Ongoing, no fixed timeline |
| Optum Health value-based care exits | Whether management is successfully exiting or renegotiating the contracts behind the $623M loss reserve | Throughout 2026 |
| Credit rating agency actions | All three agencies are on negative outlook; a downgrade increases borrowing costs on $78 billion in debt | Next review likely tied to Q1/Q2 2026 results |
| 2026 guidance reinstatement | A company confident in its trajectory provides guidance; the absence of it tells you visibility is poor | Could come with Q1 or Q2 earnings |
| Medicare Advantage membership trends | UNH signaled it expects membership to contract in 2026 as it exits unprofitable markets; the pace and magnitude of that contraction matters | Quarterly disclosures |
| Change Healthcare litigation | HIPAA breach fines, state attorney general cases, and class action settlements related to the 100M-person data breach | 2026-2027 |
| Hemsley succession planning | A 73-year-old CEO on a three-year option vesting schedule is a bridge, not a destination; who comes next matters | 2026-2028 |
Research and analysis conducted with AI assistance using SEC EDGAR filings as primary sources.